Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.
Fiche publication
Date publication
novembre 2020
Journal
EClinicalMedicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent, Dr COUDERT Bruno, Pr PETIT Thierry
Tous les auteurs :
Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Du FL, Dupré PF, Bachelot T, Gabelle P, Chauvet MP, Coeffic D, Barbe C, Prevost JB, Paintaud G, Thibault G, Ferhat A, Dupin J, Berriolo-Riedinger A, Arnould L
Lien Pubmed
Résumé
The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bevacizumab for PET-predicted poor-responders improved pathological complete response (pCR) rates (43.8% vs 24.0%). We investigated long-term study outcomes.
Mots clés
Bevacizumab, Early pet assessment, Her-2 positive breast cancer, Long-term follow-up, Neoadjuvant, Positron emission tomography, pathological complete response, Δsuvmax
Référence
EClinicalMedicine. 2020 Nov;28:100566